Systemic cancer immunotherapy with Toll-like receptor 7 agonists

TLR4 Engagement during TLR3-Induced Proinflammatory Signaling in Dendritic Cells Promotes IL-10-Mediated Suppression of Antitumor Immunity

(2011) D. Bogunovic et al.   CANCER RESEARCH

Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance

(2011) C. Bourquin et al.   CANCER RESEARCH

CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice

(2011) C. Zoglmeier et al.   CLINICAL CANCER RESEARCH

Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists

(2010) D. Rajagopal et al.   BLOOD

Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers

(2010) Melissa A. Geller et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunostimulatory RNA Oligonucleotides Induce an Effective Antitumoral NK Cell Response through the TLR7

(2009) C. Bourquin et al.   JOURNAL OF IMMUNOLOGY

Immunostimulatory RNA Blocks Suppression by Regulatory T Cells

(2009) D. Anz et al.   JOURNAL OF IMMUNOLOGY

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

(2008) R. Dummer et al.   CLINICAL CANCER RESEARCH